vs
爱尔康（ALC）与博士伦（BLCO）财务数据对比。点击上方公司名可切换其他公司
爱尔康的季度营收约是博士伦的1.8倍（$2.6B vs $1.4B）。爱尔康净利率更高（6.8% vs -4.1%，领先10.9%）。博士伦同比增速更快（9.8% vs 4.0%）
爱尔康是瑞美合资的制药及医疗器械企业，专注于眼健康护理产品领域。公司注册地为瑞士弗里堡州，全球总部设于日内瓦，核心运营基地位于美国得克萨斯州沃思堡，当地员工规模约4500人。
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
ALC vs BLCO — 直观对比
营收规模更大
ALC
是对方的1.8倍
$1.4B
营收增速更快
BLCO
高出5.8%
4.0%
净利率更高
ALC
高出10.9%
-4.1%
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $2.6B | $1.4B |
| 净利润 | $176.0M | $-58.0M |
| 毛利率 | 53.5% | — |
| 营业利润率 | 9.5% | 8.0% |
| 净利率 | 6.8% | -4.1% |
| 营收同比 | 4.0% | 9.8% |
| 净利润同比 | -21.1% | -1833.3% |
| 每股收益（稀释后） | $0.35 | $-0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALCBLCO
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | $2.5B | $1.2B | ||
| Q1 24 | — | $1.1B |
净利润ALCBLCO
| Q4 25 | — | $-58.0M | ||
| Q3 25 | — | $-28.0M | ||
| Q2 25 | $176.0M | $-62.0M | ||
| Q1 25 | — | $-212.0M | ||
| Q4 24 | — | $-3.0M | ||
| Q3 24 | — | $4.0M | ||
| Q2 24 | $223.0M | $-151.0M | ||
| Q1 24 | — | $-167.0M |
毛利率ALCBLCO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 55.0% | — | ||
| Q1 24 | — | — |
营业利润率ALCBLCO
| Q4 25 | — | 8.0% | ||
| Q3 25 | — | 7.4% | ||
| Q2 25 | 9.5% | -0.9% | ||
| Q1 25 | — | -7.3% | ||
| Q4 24 | — | 6.8% | ||
| Q3 24 | — | 3.6% | ||
| Q2 24 | 12.7% | 2.1% | ||
| Q1 24 | — | 0.5% |
净利率ALCBLCO
| Q4 25 | — | -4.1% | ||
| Q3 25 | — | -2.2% | ||
| Q2 25 | 6.8% | -4.9% | ||
| Q1 25 | — | -18.6% | ||
| Q4 24 | — | -0.2% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | 8.9% | -12.4% | ||
| Q1 24 | — | -15.2% |
每股收益（稀释后）ALCBLCO
| Q4 25 | — | $-0.16 | ||
| Q3 25 | — | $-0.08 | ||
| Q2 25 | $0.35 | $-0.18 | ||
| Q1 25 | — | $-0.60 | ||
| Q4 24 | — | $-0.00 | ||
| Q3 24 | — | $0.01 | ||
| Q2 24 | $0.45 | $-0.43 | ||
| Q1 24 | — | $-0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $383.0M |
| 总债务越低越好 | — | $5.0B |
| 股东权益账面价值 | $22.1B | $6.4B |
| 总资产 | $31.4B | $14.0B |
| 负债/权益比越低杠杆越低 | — | 0.78× |
8季度趋势，按日历期对齐
现金及短期投资ALCBLCO
| Q4 25 | — | $383.0M | ||
| Q3 25 | — | $310.0M | ||
| Q2 25 | $1.4B | $266.0M | ||
| Q1 25 | — | $202.0M | ||
| Q4 24 | — | $305.0M | ||
| Q3 24 | — | $329.0M | ||
| Q2 24 | $1.4B | $285.0M | ||
| Q1 24 | — | $315.0M |
总债务ALCBLCO
| Q4 25 | — | $5.0B | ||
| Q3 25 | — | $5.0B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | — | $4.8B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | — | $4.6B | ||
| Q2 24 | — | $4.6B | ||
| Q1 24 | — | $4.6B |
股东权益ALCBLCO
| Q4 25 | — | $6.4B | ||
| Q3 25 | — | $6.4B | ||
| Q2 25 | $22.1B | $6.4B | ||
| Q1 25 | — | $6.4B | ||
| Q4 24 | — | $6.5B | ||
| Q3 24 | — | $6.6B | ||
| Q2 24 | $20.9B | $6.5B | ||
| Q1 24 | — | $6.7B |
总资产ALCBLCO
| Q4 25 | — | $14.0B | ||
| Q3 25 | — | $13.8B | ||
| Q2 25 | $31.4B | $13.8B | ||
| Q1 25 | — | $13.4B | ||
| Q4 24 | — | $13.5B | ||
| Q3 24 | — | $13.5B | ||
| Q2 24 | $29.7B | $13.3B | ||
| Q1 24 | — | $13.3B |
负债/权益比ALCBLCO
| Q4 25 | — | 0.78× | ||
| Q3 25 | — | 0.77× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 0.71× | ||
| Q1 24 | — | 0.69× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $136.0M |
| 自由现金流经营现金流 - 资本支出 | — | $60.0M |
| 自由现金流率自由现金流/营收 | — | 4.3% |
| 资本支出强度资本支出/营收 | — | 5.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-66.0M |
8季度趋势，按日历期对齐
经营现金流ALCBLCO
| Q4 25 | — | $136.0M | ||
| Q3 25 | — | $137.0M | ||
| Q2 25 | — | $35.0M | ||
| Q1 25 | — | $-25.0M | ||
| Q4 24 | — | $22.0M | ||
| Q3 24 | — | $154.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $41.0M |
自由现金流ALCBLCO
| Q4 25 | — | $60.0M | ||
| Q3 25 | — | $63.0M | ||
| Q2 25 | — | $-54.0M | ||
| Q1 25 | — | $-135.0M | ||
| Q4 24 | — | $-70.0M | ||
| Q3 24 | — | $94.0M | ||
| Q2 24 | — | $-57.0M | ||
| Q1 24 | — | $-26.0M |
自由现金流率ALCBLCO
| Q4 25 | — | 4.3% | ||
| Q3 25 | — | 4.9% | ||
| Q2 25 | — | -4.2% | ||
| Q1 25 | — | -11.9% | ||
| Q4 24 | — | -5.5% | ||
| Q3 24 | — | 7.9% | ||
| Q2 24 | — | -4.7% | ||
| Q1 24 | — | -2.4% |
资本支出强度ALCBLCO
| Q4 25 | — | 5.4% | ||
| Q3 25 | — | 5.8% | ||
| Q2 25 | — | 7.0% | ||
| Q1 25 | — | 9.7% | ||
| Q4 24 | — | 7.2% | ||
| Q3 24 | — | 5.0% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 6.1% |
现金转化率ALCBLCO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 38.50× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALC
暂无分部数据
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
